HM15275 vs retatrutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline

HM15275

Developed by Hanmi Pharmaceutical

Phase 2 in Obesitypeptide
Weak signal

NCT06481098 · Phase 1 · completed

The trial randomized participants against a matched placebo with full blinding, but its primary measures were safety and tolerability rather than a body-weight or metabolic efficacy outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Part A: Safety and Tolerability" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: January 2027 · NCT07205900 (registry estimate)

Reported efficacy

Part A: Safety and Tolerability (Up to Day 29); Part B: Safety and Tolerability (Up to Day 57): Phase 1 single and multiple ascending dose study of HM15275: the single-dose part included 24 healthy volunteers (66.7% male, BMI 24.0 kg/m2) and the multiple-dose part 50 obese adults (62.0% male, BMI 33.3 kg/m2). The most common adverse events in HM15275 recipients were mild to moderate gastrointestinal symptoms, with no clinically significant changes in vital signs or laboratory parameters, and no serious adverse events or discontinuations due to treatment-related adverse events in either part.

Result source: NCT06481098

retatrutide

Developed by Eli Lilly

Phase 3 in Obesitypeptide
Partial signal

NCT05882045 · Phase 3 · completed

The study was randomized, double-blind, and placebo-controlled, with 1,946 participants enrolled, and its primary endpoint was the clinical obesity outcome of percent change in body weight. The primary comparison favored retatrutide and met its primary endpoint per the sponsor's topline release (no p-value published), but no power calculation or planned enrollment target is provided in the available record, so the evidence is graded moderate rather than strong.

Next expected readout: November 2026 · NCT06662383 (registry estimate)

Reported efficacy

Percent Change from Baseline in Body Weight (Baseline, Week 80); Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (Baseline, Week 80): Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. (met)

Result source: NCT05929079

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHM15275retatrutide
Body weight, % change—Not reported-17.4% vs -1.6%−15.8 vs placebo12 mg (2 mg) · wk 24 · n 62NCT04881760
14 other results
  • -16.6% vs -1.6% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · primary NCT04881760
  • -18.3% vs -1.6% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · primary NCT04881760
  • -12% vs -1.6% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · primary NCT04881760
  • -13.8% vs -1.6% 4 mg · wk 24 · n 33 · Phase 2 · primary NCT04881760
  • -7.2% vs -1.6% 1 mg · wk 24 · n 69 · Phase 2 · primary NCT04881760
  • -24.2% vs -2.1% 12 mg (2 mg) · wk 48 · n 62 · Phase 2 · secondary NCT04881760
  • -21.7% vs -2.1% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -23.9% vs -2.1% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -16.3% vs -2.1% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -17.8% vs -2.1% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -8.7% vs -2.1% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • -20.8% vs -4% 12 mg · wk 80 · Phase 3 · primary NCT05929079
  • -19.1% vs -4% 9 mg · wk 80 · Phase 3 · primary NCT05929079
  • -12.7% vs -4% retatrutide 4 mg · wk 80 · Phase 3 · primary NCT05929079
Weight loss of 5% or more—Not reported100% vs 27%+73 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • 97% vs 26% 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • 100% vs 27% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 27% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 26% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 26% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 87% vs 27% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 97% vs 27% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 87% vs 26% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 94% vs 26% 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 64% vs 27% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • 59% vs 26% 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760
Weight loss of 10% or more—Not reported93% vs 9%+84 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • 90% vs 3% 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • 90% vs 9% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 91% vs 9% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 83% vs 3% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 94% vs 3% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 73% vs 9% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 76% vs 9% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 59% vs 3% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 72% vs 3% 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 27% vs 9% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • 25% vs 3% 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760
Waist circumference, change (cm)—Not reported-19.6 vs -2.6−17 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • -14.3 vs -2.6 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • -18.5 vs -2.6 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -18.5 vs -2.6 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -13.7 vs -2.6 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • -15.0 vs -2.6 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • -14.6 vs -2.6 4 mg (2 mg) · wk 48 · n 32 · Phase 2 · secondary NCT04881760
  • -14.9 vs -2.6 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -10.3 vs -2.6 4 mg (2 mg) · wk 24 · n 32 · Phase 2 · secondary NCT04881760
  • -12.6 vs -2.6 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • -6.5 vs -2.6 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • -5.4 vs -2.6 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760

Body weight, % change

HM15275
—Not reported
retatrutide
-17.4% vs -1.6%−15.8 vs placebo12 mg (2 mg) · wk 24 · n 62NCT04881760
14 other results
  • -16.6% vs -1.6% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · primary NCT04881760
  • -18.3% vs -1.6% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · primary NCT04881760
  • -12% vs -1.6% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · primary NCT04881760
  • -13.8% vs -1.6% 4 mg · wk 24 · n 33 · Phase 2 · primary NCT04881760
  • -7.2% vs -1.6% 1 mg · wk 24 · n 69 · Phase 2 · primary NCT04881760
  • -24.2% vs -2.1% 12 mg (2 mg) · wk 48 · n 62 · Phase 2 · secondary NCT04881760
  • -21.7% vs -2.1% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -23.9% vs -2.1% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -16.3% vs -2.1% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -17.8% vs -2.1% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -8.7% vs -2.1% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • -20.8% vs -4% 12 mg · wk 80 · Phase 3 · primary NCT05929079
  • -19.1% vs -4% 9 mg · wk 80 · Phase 3 · primary NCT05929079
  • -12.7% vs -4% retatrutide 4 mg · wk 80 · Phase 3 · primary NCT05929079

Weight loss of 5% or more

HM15275
—Not reported
retatrutide
100% vs 27%+73 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • 97% vs 26% 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • 100% vs 27% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 27% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 26% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 100% vs 26% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 87% vs 27% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 97% vs 27% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 87% vs 26% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 94% vs 26% 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 64% vs 27% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • 59% vs 26% 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760

Weight loss of 10% or more

HM15275
—Not reported
retatrutide
93% vs 9%+84 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • 90% vs 3% 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • 90% vs 9% 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 91% vs 9% 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • 83% vs 3% 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 94% vs 3% 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • 73% vs 9% 4 mg (2 mg) · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 76% vs 9% 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • 59% vs 3% 4 mg (2 mg) · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 72% vs 3% 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • 27% vs 9% 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • 25% vs 3% 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760

Waist circumference, change (cm)

HM15275
—Not reported
retatrutide
-19.6 vs -2.6−17 vs placebo12 mg (2 mg) · wk 48 · n 62NCT04881760
11 other results
  • -14.3 vs -2.6 12 mg (2 mg) · wk 24 · n 62 · Phase 2 · secondary NCT04881760
  • -18.5 vs -2.6 8 mg (2 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -18.5 vs -2.6 8 mg (4 mg) · wk 48 · n 35 · Phase 2 · secondary NCT04881760
  • -13.7 vs -2.6 8 mg (2 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • -15.0 vs -2.6 8 mg (4 mg) · wk 24 · n 35 · Phase 2 · secondary NCT04881760
  • -14.6 vs -2.6 4 mg (2 mg) · wk 48 · n 32 · Phase 2 · secondary NCT04881760
  • -14.9 vs -2.6 4 mg · wk 48 · n 33 · Phase 2 · secondary NCT04881760
  • -10.3 vs -2.6 4 mg (2 mg) · wk 24 · n 32 · Phase 2 · secondary NCT04881760
  • -12.6 vs -2.6 4 mg · wk 24 · n 33 · Phase 2 · secondary NCT04881760
  • -6.5 vs -2.6 1 mg · wk 48 · n 69 · Phase 2 · secondary NCT04881760
  • -5.4 vs -2.6 1 mg · wk 24 · n 69 · Phase 2 · secondary NCT04881760
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HM15275: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HM15275: 0 of 4 rows · retatrutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricretatrutide
Dropout rate
12.9%12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 5 more results
14.3%8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
17.1%8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
23.5%4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
21.2%4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
13%1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Discontinued due to AEs
3.2%12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 5 more results
2.9%8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
2.9%8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
0%4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
3%4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
1.4%1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Serious AEs
3.2%12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 5 more results
2.9%8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
5.7%8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
6.1%4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
0%4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
4.3%1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Most frequent reported AEs
12 mg (2 mg)
nausea 45.2% (placebo 11.4%)
decreased appetite 29% (placebo 8.6%)
covid-19 24.2% (placebo 20%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 5 more results
8 mg (2 mg)
diarrhoea 20% (placebo 11.4%)
covid-19 17.1% (placebo 20%)
nausea 17.1% (placebo 11.4%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
8 mg (4 mg)
nausea 60% (placebo 11.4%)
covid-19 31.4% (placebo 20%)
decreased appetite 31.4% (placebo 8.6%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
4 mg
nausea 36.4% (placebo 11.4%)
decreased appetite 24.2% (placebo 8.6%)
covid-19 18.2% (placebo 20%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
4 mg (2 mg)
decreased appetite 18.2% (placebo 8.6%)
nausea 18.2% (placebo 11.4%)
constipation 15.2% (placebo 2.9%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
1 mg
covid-19 18.8% (placebo 20%)
nausea 14.5% (placebo 11.4%)
decreased appetite 13% (placebo 8.6%)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

retatrutide

Weight -17.39% (n=62) vs -1.55% (n=68) placebo @ 24wk12 mg (2 mg)
percent change · % of baseline
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 14 more results
-24.22% (n=62) vs -2.11% (n=68) placebo @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-20.8% vs -4% placebo @ 80wk12 mg
NCT05929079 · Phase 3 · sponsor-reported, not registry data
-19.1% vs -4% placebo @ 80wk9 mg
NCT05929079 · Phase 3 · sponsor-reported, not registry data
-16.64% (n=35) vs -1.55% (n=68) placebo @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-18.26% (n=35) vs -1.55% (n=68) placebo @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-21.72% (n=35) vs -2.11% (n=68) placebo @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-23.88% (n=35) vs -2.11% (n=68) placebo @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-12% (n=33) vs -1.55% (n=68) placebo @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-13.8% (n=33) vs -1.55% (n=68) placebo @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-16.32% (n=33) vs -2.11% (n=68) placebo @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-17.83% (n=33) vs -2.11% (n=68) placebo @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-12.7% vs -4% placebo @ 80wkretatrutide 4 mg
NCT05929079 · Phase 3 · sponsor-reported, not registry data
-7.18% (n=69) vs -1.55% (n=68) placebo @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-8.67% (n=69) vs -2.11% (n=68) placebo @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 5% 97% (n=62) vs 26% (n=68) placebo @ 24wk12 mg (2 mg)
responder rate · % of participants
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
100% (n=62) vs 27% (n=68) placebo @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
100% (n=35) vs 26% (n=68) placebo @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
100% (n=35) vs 26% (n=68) placebo @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
100% (n=35) vs 27% (n=68) placebo @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
100% (n=35) vs 27% (n=68) placebo @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
87% (n=33) vs 26% (n=68) placebo @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
94% (n=33) vs 26% (n=68) placebo @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
87% (n=33) vs 27% (n=68) placebo @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
97% (n=33) vs 27% (n=68) placebo @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
59% (n=69) vs 26% (n=68) placebo @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
64% (n=69) vs 27% (n=68) placebo @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 10% 90% (n=62) vs 3% (n=68) placebo @ 24wk12 mg (2 mg)
responder rate · % of participants
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
93% (n=62) vs 9% (n=68) placebo @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
83% (n=35) vs 3% (n=68) placebo @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
94% (n=35) vs 3% (n=68) placebo @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
90% (n=35) vs 9% (n=68) placebo @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
91% (n=35) vs 9% (n=68) placebo @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
59% (n=33) vs 3% (n=68) placebo @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
72% (n=33) vs 3% (n=68) placebo @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
73% (n=33) vs 9% (n=68) placebo @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
76% (n=33) vs 9% (n=68) placebo @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
25% (n=69) vs 3% (n=68) placebo @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
27% (n=69) vs 9% (n=68) placebo @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 15% 70% (n=62) vs 1% (n=68) placebo @ 24wk12 mg (2 mg)
responder rate · % of participants
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
83% (n=62) vs 2% (n=68) placebo @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
51% (n=35) vs 1% (n=68) placebo @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
68% (n=35) vs 1% (n=68) placebo @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
73% (n=35) vs 2% (n=68) placebo @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
77% (n=35) vs 2% (n=68) placebo @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
29% (n=33) vs 1% (n=68) placebo @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
44% (n=33) vs 1% (n=68) placebo @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
55% (n=33) vs 2% (n=68) placebo @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
64% (n=33) vs 2% (n=68) placebo @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
10% (n=69) vs 1% (n=68) placebo @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
16% (n=69) vs 2% (n=68) placebo @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Weight -18.53 vs -1.27 placebo kg @ 24wk12 mg (2 mg)
absolute change · kg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
-26.17 vs -1.84 placebo kg @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-17.7 vs -1.27 placebo kg @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-19.75 vs -1.27 placebo kg @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-23.52 vs -1.84 placebo kg @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-25.88 vs -1.84 placebo kg @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-12.59 vs -1.27 placebo kg @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-14.79 vs -1.27 placebo kg @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-17.32 vs -1.84 placebo kg @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-19.13 vs -1.84 placebo kg @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-7.72 vs -1.27 placebo kg @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-9.37 vs -1.84 placebo kg @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
BMI -6.44 vs -0.49 placebo kg @ 24wk12 mg (2 mg)
absolute change · kg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
-9.14 vs -0.72 placebo kg @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.15 vs -0.49 placebo kg @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.84 vs -0.49 placebo kg @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-8.12 vs -0.72 placebo kg @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-9.02 vs -0.72 placebo kg @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-4.47 vs -0.49 placebo kg @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-5.13 vs -0.49 placebo kg @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.14 vs -0.72 placebo kg @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.67 vs -0.72 placebo kg @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-2.64 vs -0.49 placebo kg @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-3.22 vs -0.72 placebo kg @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
Waist Circumference Change -14.33 vs -2.6 placebo cm @ 24wk12 mg (2 mg)
absolute change · cm
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
-19.6 vs -2.64 placebo cm @ 48wk12 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-13.74 vs -2.6 placebo cm @ 24wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-14.99 vs -2.6 placebo cm @ 24wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-18.53 vs -2.64 placebo cm @ 48wk8 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-18.5 vs -2.64 placebo cm @ 48wk8 mg (4 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-10.33 vs -2.6 placebo cm @ 24wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-12.55 vs -2.6 placebo cm @ 24wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-14.58 vs -2.64 placebo cm @ 48wk4 mg (2 mg)
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-14.87 vs -2.64 placebo cm @ 48wk4 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-5.43 vs -2.6 placebo cm @ 24wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
-6.49 vs -2.64 placebo cm @ 48wk1 mg
NCT04881760 · Phase 2 · monotherapy · Obesity · phase 2
WOMAC Pain -3.7 vs -2.1 placebo score @ 68wkretatrutide 12 mg
absolute change · score
NCT05931367 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-4 vs -2.1 placebo score @ 68wkretatrutide 9 mg
NCT05931367 · Phase 3 · sponsor-reported, not registry data

Type 2 Diabetes

Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Type 2 Diabetes pipeline

HM15275

Developed by Hanmi Pharmaceutical

Phase 2 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: October 2027 · NCT07527650 (registry estimate)

No aligned efficacy figure on record for this race.

retatrutide

Developed by Eli Lilly

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT04867785 · Phase 2 · completed

The study randomized 281 participants and used double blinding with both placebo and dulaglutide control arms. Its primary HbA1c endpoint was statistically significant versus placebo for the 4–12 mg retatrutide doses but not for 0.5 mg, producing a mixed dose-level result rather than a uniformly positive primary comparison.

Next expected readout: January 2027 · NCT06982859 (registry estimate)

Reported efficacy

Percent Change from Baseline in Body Weight (Baseline, Week 80); Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (Baseline, Week 80): Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract. (met)

Result source: NCT05929079

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHM15275retatrutide
HbA1c, change—Not reported-2.0% vs -0.1%−2 vs placebo12 mg (2 mg) · wk 24 · n 43NCT04867785
20 other results
  • -2.0% vs -0.1% 8 mg (2 mg) · wk 24 · n 25 · Phase 2 · primary NCT04867785
  • -1.9% vs -0.1% 8 mg (4 mg) · wk 24 · n 24 · Phase 2 · primary NCT04867785
  • -1.4% vs -0.1% 4 mg (2 mg) · wk 24 · n 22 · Phase 2 · primary NCT04867785
  • -1.3% vs -0.1% 4 mg (4 mg) · wk 24 · n 24 · Phase 2 · primary NCT04867785
  • -0.4% vs -0.1% 0.5 mg · wk 24 · n 46 · Phase 2 · primary NCT04867785
  • -2.2% vs -0.3% 12 mg (2 mg) · wk 36 · n 43 · Phase 2 · secondary NCT04867785
  • -2.0% vs -0.1% 12 mg (2 mg) · wk 24 · n 43 · Phase 2 · secondary NCT04867785
  • -2.1% vs -0.3% 8 mg (2 mg) · wk 36 · n 25 · Phase 2 · secondary NCT04867785
  • -1.9% vs -0.3% 8 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • -2.0% vs -0.1% 8 mg (2 mg) · wk 24 · n 25 · Phase 2 · secondary NCT04867785
  • -1.9% vs -0.1% 8 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • -1.3% vs -0.3% 4 mg (2 mg) · wk 36 · n 22 · Phase 2 · secondary NCT04867785
  • -1.5% vs -0.3% 4 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • -1.4% vs -0.1% 4 mg (2 mg) · wk 24 · n 22 · Phase 2 · secondary NCT04867785
  • -1.3% vs -0.1% 4 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • -0.5% vs -0.3% 0.5 mg · wk 36 · n 46 · Phase 2 · secondary NCT04867785
  • -0.4% vs -0.1% 0.5 mg · wk 24 · n 46 · Phase 2 · secondary NCT04867785
  • -1.9% vs -0.8% 12 mg · wk 40 · Phase 3 · primary NCT06354660
  • -2% vs -0.8% 9 mg · wk 40 · Phase 3 · primary NCT06354660
  • -1.7% vs -0.8% 4 mg · wk 40 · Phase 3 · primary NCT06354660
Body weight, change (kg)—Not reported-17.2 vs -3.3−13.9 vs placebo12 mg (2 mg) · wk 36 · n 43NCT04867785
11 other results
  • -12.8 vs -1.9 12 mg (2 mg) · wk 24 · n 43 · Phase 2 · secondary NCT04867785
  • -16.5 vs -3.3 8 mg (2 mg) · wk 36 · n 25 · Phase 2 · secondary NCT04867785
  • -16.1 vs -3.3 8 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • -12.0 vs -1.9 8 mg (2 mg) · wk 24 · n 25 · Phase 2 · secondary NCT04867785
  • -13.9 vs -1.9 8 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • -7.3 vs -3.3 4 mg (2 mg) · wk 36 · n 22 · Phase 2 · secondary NCT04867785
  • -10.4 vs -3.3 4 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • -6.3 vs -1.9 4 mg (2 mg) · wk 24 · n 22 · Phase 2 · secondary NCT04867785
  • -8.6 vs -1.9 4 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • -3.3 vs -3.3 0.5 mg · wk 36 · n 46 · Phase 2 · secondary NCT04867785
  • -2.4 vs -1.9 0.5 mg · wk 24 · n 46 · Phase 2 · secondary NCT04867785
HbA1c below 7%—Not reported80% vs 22%+58 vs placebo12 mg (2 mg) · wk 36 · n 43NCT04867785
11 other results
  • 86% vs 18% 12 mg (2 mg) · wk 24 · n 43 · Phase 2 · secondary NCT04867785
  • 82% vs 22% 8 mg (2 mg) · wk 36 · n 25 · Phase 2 · secondary NCT04867785
  • 78% vs 22% 8 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • 88% vs 18% 8 mg (2 mg) · wk 24 · n 25 · Phase 2 · secondary NCT04867785
  • 78% vs 18% 8 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • 61% vs 22% 4 mg (2 mg) · wk 36 · n 22 · Phase 2 · secondary NCT04867785
  • 59% vs 22% 4 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • 53% vs 18% 4 mg (2 mg) · wk 24 · n 22 · Phase 2 · secondary NCT04867785
  • 66% vs 18% 4 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • 37% vs 22% 0.5 mg · wk 36 · n 46 · Phase 2 · secondary NCT04867785
  • 32% vs 18% 0.5 mg · wk 24 · n 46 · Phase 2 · secondary NCT04867785
Fasting plasma glucose, change—Not reported—Not posted · NCT06354660
3-point MACE (% with event)—Not reported—Not posted · NCT06354660

HbA1c, change

HM15275
—Not reported
retatrutide
-2.0% vs -0.1%−2 vs placebo12 mg (2 mg) · wk 24 · n 43NCT04867785
20 other results
  • -2.0% vs -0.1% 8 mg (2 mg) · wk 24 · n 25 · Phase 2 · primary NCT04867785
  • -1.9% vs -0.1% 8 mg (4 mg) · wk 24 · n 24 · Phase 2 · primary NCT04867785
  • -1.4% vs -0.1% 4 mg (2 mg) · wk 24 · n 22 · Phase 2 · primary NCT04867785
  • -1.3% vs -0.1% 4 mg (4 mg) · wk 24 · n 24 · Phase 2 · primary NCT04867785
  • -0.4% vs -0.1% 0.5 mg · wk 24 · n 46 · Phase 2 · primary NCT04867785
  • -2.2% vs -0.3% 12 mg (2 mg) · wk 36 · n 43 · Phase 2 · secondary NCT04867785
  • -2.0% vs -0.1% 12 mg (2 mg) · wk 24 · n 43 · Phase 2 · secondary NCT04867785
  • -2.1% vs -0.3% 8 mg (2 mg) · wk 36 · n 25 · Phase 2 · secondary NCT04867785
  • -1.9% vs -0.3% 8 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • -2.0% vs -0.1% 8 mg (2 mg) · wk 24 · n 25 · Phase 2 · secondary NCT04867785
  • -1.9% vs -0.1% 8 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • -1.3% vs -0.3% 4 mg (2 mg) · wk 36 · n 22 · Phase 2 · secondary NCT04867785
  • -1.5% vs -0.3% 4 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • -1.4% vs -0.1% 4 mg (2 mg) · wk 24 · n 22 · Phase 2 · secondary NCT04867785
  • -1.3% vs -0.1% 4 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • -0.5% vs -0.3% 0.5 mg · wk 36 · n 46 · Phase 2 · secondary NCT04867785
  • -0.4% vs -0.1% 0.5 mg · wk 24 · n 46 · Phase 2 · secondary NCT04867785
  • -1.9% vs -0.8% 12 mg · wk 40 · Phase 3 · primary NCT06354660
  • -2% vs -0.8% 9 mg · wk 40 · Phase 3 · primary NCT06354660
  • -1.7% vs -0.8% 4 mg · wk 40 · Phase 3 · primary NCT06354660

Body weight, change (kg)

HM15275
—Not reported
retatrutide
-17.2 vs -3.3−13.9 vs placebo12 mg (2 mg) · wk 36 · n 43NCT04867785
11 other results
  • -12.8 vs -1.9 12 mg (2 mg) · wk 24 · n 43 · Phase 2 · secondary NCT04867785
  • -16.5 vs -3.3 8 mg (2 mg) · wk 36 · n 25 · Phase 2 · secondary NCT04867785
  • -16.1 vs -3.3 8 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • -12.0 vs -1.9 8 mg (2 mg) · wk 24 · n 25 · Phase 2 · secondary NCT04867785
  • -13.9 vs -1.9 8 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • -7.3 vs -3.3 4 mg (2 mg) · wk 36 · n 22 · Phase 2 · secondary NCT04867785
  • -10.4 vs -3.3 4 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • -6.3 vs -1.9 4 mg (2 mg) · wk 24 · n 22 · Phase 2 · secondary NCT04867785
  • -8.6 vs -1.9 4 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • -3.3 vs -3.3 0.5 mg · wk 36 · n 46 · Phase 2 · secondary NCT04867785
  • -2.4 vs -1.9 0.5 mg · wk 24 · n 46 · Phase 2 · secondary NCT04867785

HbA1c below 7%

HM15275
—Not reported
retatrutide
80% vs 22%+58 vs placebo12 mg (2 mg) · wk 36 · n 43NCT04867785
11 other results
  • 86% vs 18% 12 mg (2 mg) · wk 24 · n 43 · Phase 2 · secondary NCT04867785
  • 82% vs 22% 8 mg (2 mg) · wk 36 · n 25 · Phase 2 · secondary NCT04867785
  • 78% vs 22% 8 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • 88% vs 18% 8 mg (2 mg) · wk 24 · n 25 · Phase 2 · secondary NCT04867785
  • 78% vs 18% 8 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • 61% vs 22% 4 mg (2 mg) · wk 36 · n 22 · Phase 2 · secondary NCT04867785
  • 59% vs 22% 4 mg (4 mg) · wk 36 · n 24 · Phase 2 · secondary NCT04867785
  • 53% vs 18% 4 mg (2 mg) · wk 24 · n 22 · Phase 2 · secondary NCT04867785
  • 66% vs 18% 4 mg (4 mg) · wk 24 · n 24 · Phase 2 · secondary NCT04867785
  • 37% vs 22% 0.5 mg · wk 36 · n 46 · Phase 2 · secondary NCT04867785
  • 32% vs 18% 0.5 mg · wk 24 · n 46 · Phase 2 · secondary NCT04867785

Fasting plasma glucose, change

HM15275
—Not reported
retatrutide
—Not posted · NCT06354660

3-point MACE (% with event)

HM15275
—Not reported
retatrutide
—Not posted · NCT06354660
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HM15275: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HM15275: 0 of 4 rows · retatrutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricretatrutide
Dropout rate
23.9%12 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
show 5 more results
3.8%8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
8.3%8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
17.4%4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
12.5%4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
12.8%0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
Discontinued due to AEs
4.3%12 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
show 5 more results
0%8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
0%8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
0%4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
0%4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
2.1%0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
Serious AEs
4.3%12 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
show 5 more results
7.7%8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
4.2%8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
4.3%4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
8.3%4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
6.4%0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
Most frequent reported AEs
12 mg (2 mg)
decreased appetite 19.6% (placebo 0%)
nausea 19.6% (placebo 4.4%)
diarrhoea 15.2% (placebo 4.4%)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
show 5 more results
8 mg (2 mg)
nausea 26.9% (placebo 4.4%)
decreased appetite 19.2% (placebo 0%)
diarrhoea 19.2% (placebo 4.4%)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
8 mg (4 mg)
nausea 41.7% (placebo 4.4%)
diarrhoea 29.2% (placebo 4.4%)
decreased appetite 16.7% (placebo 0%)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
4 mg (2 mg)
covid-19 13% (placebo 6.7%)
constipation 8.7% (placebo 2.2%)
cough 8.7% (placebo 0%)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
4 mg (4 mg)
diarrhoea 25% (placebo 4.4%)
nausea 25% (placebo 4.4%)
decreased appetite 20.8% (placebo 0%)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
0.5 mg
covid-19 10.6% (placebo 6.7%)
constipation 6.4% (placebo 2.2%)
decreased appetite 4.3% (placebo 0%)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

retatrutide

HbA1c -2.01% (n=43) vs -0.05% (n=45) placebo @ 24wk12 mg (2 mg)
absolute change · percentage points
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
show 20 more results
-2.01% (n=43) vs -0.05% (n=45) placebo @ 24wk12 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-2.16% (n=43) vs -0.3% (n=45) placebo @ 36wk12 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.9% vs -0.8% placebo @ 40wk12 mg
NCT06354660 · Phase 3 · sponsor-reported, not registry data
-2% vs -0.8% placebo @ 40wk9 mg
NCT06354660 · Phase 3 · sponsor-reported, not registry data
-1.99% (n=25) vs -0.05% (n=45) placebo @ 24wk8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.88% (n=24) vs -0.05% (n=45) placebo @ 24wk8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.99% (n=25) vs -0.05% (n=45) placebo @ 24wk8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.88% (n=24) vs -0.05% (n=45) placebo @ 24wk8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-2.13% (n=25) vs -0.3% (n=45) placebo @ 36wk8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.93% (n=24) vs -0.3% (n=45) placebo @ 36wk8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.39% (n=22) vs -0.05% (n=45) placebo @ 24wk4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.3% (n=24) vs -0.05% (n=45) placebo @ 24wk4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.39% (n=22) vs -0.05% (n=45) placebo @ 24wk4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.3% (n=24) vs -0.05% (n=45) placebo @ 24wk4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.3% (n=22) vs -0.3% (n=45) placebo @ 36wk4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.5% (n=24) vs -0.3% (n=45) placebo @ 36wk4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-1.7% vs -0.8% placebo @ 40wk4 mg
NCT06354660 · Phase 3 · sponsor-reported, not registry data
-0.43% (n=46) vs -0.05% (n=45) placebo @ 24wk0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-0.43% (n=46) vs -0.05% (n=45) placebo @ 24wk0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-0.54% (n=46) vs -0.3% (n=45) placebo @ 36wk0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
HbA1c Less Than 7% 86% (n=43) vs 18% (n=45) placebo @ 24wk12 mg (2 mg)
responder rate · % of participants
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
show 11 more results
80% (n=43) vs 22% (n=45) placebo @ 36wk12 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
88% (n=25) vs 18% (n=45) placebo @ 24wk8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
78% (n=24) vs 18% (n=45) placebo @ 24wk8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
82% (n=25) vs 22% (n=45) placebo @ 36wk8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
78% (n=24) vs 22% (n=45) placebo @ 36wk8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
53% (n=22) vs 18% (n=45) placebo @ 24wk4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
66% (n=24) vs 18% (n=45) placebo @ 24wk4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
61% (n=22) vs 22% (n=45) placebo @ 36wk4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
59% (n=24) vs 22% (n=45) placebo @ 36wk4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
32% (n=46) vs 18% (n=45) placebo @ 24wk0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
37% (n=46) vs 22% (n=45) placebo @ 36wk0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
FBG Change mg/dL -65.2 vs -10.59 placebo mg @ 24wk12 mg (2 mg)
absolute change · mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
show 5 more results
-66.09 vs -10.59 placebo mg @ 24wk8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-39.8 vs -10.59 placebo mg @ 24wk8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-30.19 vs -10.59 placebo mg @ 24wk4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-43.89 vs -10.59 placebo mg @ 24wk4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-12.71 vs -10.59 placebo mg @ 24wk0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
FBG Change mg/dL -67.84 vs -17.26 placebo mg/dL @ 36wk12 mg (2 mg)
absolute change · mg/dL
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
show 5 more results
-69.1 vs -17.26 placebo mg/dL @ 36wk8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-41.2 vs -17.26 placebo mg/dL @ 36wk8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-21.46 vs -17.26 placebo mg/dL @ 36wk4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-38.72 vs -17.26 placebo mg/dL @ 36wk4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-17.51 vs -17.26 placebo mg/dL @ 36wk0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
Weight -12.84 vs -1.86 placebo kg @ 24wk12 mg (2 mg)
absolute change · kg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
show 11 more results
-17.18 vs -3.28 placebo kg @ 36wk12 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-11.99 vs -1.86 placebo kg @ 24wk8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-13.91 vs -1.86 placebo kg @ 24wk8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-16.48 vs -3.28 placebo kg @ 36wk8 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-16.12 vs -3.28 placebo kg @ 36wk8 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-6.27 vs -1.86 placebo kg @ 24wk4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-8.64 vs -1.86 placebo kg @ 24wk4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-7.28 vs -3.28 placebo kg @ 36wk4 mg (2 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-10.37 vs -3.28 placebo kg @ 36wk4 mg (4 mg)
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-2.35 vs -1.86 placebo kg @ 24wk0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
-3.31 vs -3.28 placebo kg @ 36wk0.5 mg
NCT04867785 · Phase 2 · monotherapy · Type 2 Diabetes · phase 2
Weight -20.8% vs -4% placebo @ 80wk12 mg
percent change · % of baseline
NCT05929079 · Phase 3 · sponsor-reported, not registry data
show 2 more results
-19.1% vs -4% placebo @ 80wk9 mg
NCT05929079 · Phase 3 · sponsor-reported, not registry data
-12.7% vs -4% placebo @ 80wkretatrutide 4 mg
NCT05929079 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HM15275's landscape · retatrutide's landscape